Active Ingredient History
Rilotumumab is a human monoclonal antibody designed for the treatment of solid tumors. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Carcinoma, Non-Small-Cell Lung (Phase 1/Phase 2)
Carcinoma, Renal Cell (Phase 2)
Colonic Neoplasms (Phase 1/Phase 2)
Colorectal Neoplasms (Phase 1/Phase 2)
Esophageal Neoplasms (Phase 1/Phase 2)
Fallopian Tube Neoplasms (Phase 2)
Gastrointestinal Neoplasms (Phase 1/Phase 2)
Glioblastoma (Phase 2)
Glioma (Phase 2)
Gliosarcoma (Phase 2)
Hamartoma (Phase 2)
Lung Neoplasms (Phase 2/Phase 3)
Mesothelioma (Phase 2)
Neoplasm Metastasis (Phase 2)
Neoplasms (Phase 1/Phase 2)
Ovarian Neoplasms (Phase 2)
Prostatic Neoplasms (Phase 1/Phase 2)
Prostatic Neoplasms, Castration-Resistant (Phase 1/Phase 2)
Proto-Oncogene Proteins c-met (Phase 2/Phase 3)
Rectal Neoplasms (Phase 1/Phase 2)
Small Cell Lung Carcinoma (Phase 1/Phase 2)
Stomach Neoplasms (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue